OptiNose

OptiNose — Q4 2018 Earnings Presentation

18 slides from OptiNose's earnings presentation, Mar 6, 2019

  1. Slide 1: Building a Leading ENT / Allergy Specialty Company

    Exhibit 99.2 Building a Leading ENT / Allergy Specialty Company Corporate Presentation M a r c h 6 , 2 0 1 9

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this pu

  3. Slide 3: Optinose Key Priorities

    Optinose Key Priorities Continue to drive XHANCE® prescription growth Advance our XHANCE clinical program for a follow-on indication for the treatment of Chronic Sinusitis Support our commercial and development objectives through efficient use of capital ■ $201 Million of cash as of December 31, 201

  4. Slide 4: XHANCE Launch Update

    XHANCE Launch Update

  5. Slide 5: Key Levers to Continue to Drive XHANCE Growth

    Key Levers to Continue to Drive XHANCE Growth Continued Execution of Strategy (Defined Appropriate Patient Type, Enhanced Efficacy Message & Affordability Program) Sales Force Expansion 7-Day Samples Increase Payer Coverage Direct to Consumer Pilot 5

  6. Slide 6: XHANCE Prescription Volume Grew 50% in Q4 2018 Versus Q3

    XHANCE Prescription Volume Grew 50% in Q4 2018 Versus Q3 2018 Accelerated growth in fourth quarter 2018 driven by promotional materials and patient affordability program rolled out in August/September 2018 XHANCE TRx +50% 16,000 14,106 14,000 12,000 10,000 9,427 8,611 8,000 6,000 4,000 2,000 0 Q2 Q3

  7. Slide 7: XHANCE Prescription Volume Grew 38% in Jan 2019 vs Dec 2018

    XHANCE Prescription Volume Grew 38% in Jan 2019 vs Dec 2018 and 40% for the Most Recent 4 week Period Ending Feb 22, 2019 January 2019 TRx increased 38% versus XHANCE TRx increased 39% in the most December 2018 TRx recent 4-Week over 4-Week period XHANCE TRx +38% XHANCE TRx +39% 8,000 8,000 7,186 6,

  8. Slide 8: Additional Commercial Updates

    Additional Commercial Updates Market Access Sales Force Expansion ▪ Nationally, we believe more than 75% of ▪ Expect to deploy Territory Managers in commercial lives are in a plan where new territories in April XHANCE is covered in a Tier 3 formulary ▪ Increase of ~25% in deployed territories positi

  9. Slide 9: Q4 2018 Financial Update

    Q4 2018 Financial Update

  10. Slide 10: Financial Review – Q4 2018 Net Revenues and Average Net Revenue per Prescription

    Financial Review – Fourth Quarter and Full Year 2018 Q4 2018 Net Revenues and Average Net Revenue per Prescription ▪ ($ 000’s) Net Revenues Net revenue increased 59% in Q4 versus Q3 2018 $3,024 ▪ Average net revenue of ~$214 per TRx in Q4 increased ~6% compared to average revenue of ~$202 per $1,902

  11. Slide 11: Financial Review – Full Year 2018 Operating Expenses

    Financial Review – Fourth Quarter and Full Year 2018 Full year 2018 Operating Expenses were $105.7M, favorable versus expected range of $112M to $115M ($M) Operating Expenses $105.7 $27.0 Q4 2018 FY 2018 11

  12. Slide 12: Financial Review – 2019 Financial Guidance

    Financial Review – 2019 Financial Guidance ▪ Full Year 2019 Operating Expenses (GAAP) expected to be in the range of $135 - $142 million • $10 - $12 million of which represents stock-based compensation ▪ Q1 2019 average net revenue per prescription of XHANCE expected to be in the range of $155 - $17

  13. Slide 13: Pipeline Update

    Pipeline Update

  14. Slide 14: XHANCE Chronic Sinusitis Indication (sNDA)

    XHANCE Chronic Sinusitis Indication (sNDA) Study 3205 - ClinicalTrials.gov Identifier: NCT03781804 ▪ 24-week randomized, double-blind, placebo-controlled, parallel-group, multicenter study ▪ First patient enrolled in Q4 2018 ▪ Estimated enrollment: 378 patients ▪ Key actions in Q1 2019 include the i

  15. Slide 15: Closing Remarks

    Closing Remarks

  16. Slide 16: Building a leading ENT/Allergy Specialty Company

    Building a leading ENT/Allergy Specialty Company XHANCE® represents a significant opportunity in the ENT/Allergy market with the current indication Potential for CS indication provides pipeline value Additional business development expected to focus on leveraging ENT/Allergy infrastructure and exper

  17. Slide 17: Investor Relations

    Investor Relations – NASDAQ: OPTN At 31 December 2018: Analyst Coverage1 – $201 million in cash – Long-term debt: $75 million BMO: Gary Nachman – 41.3 million common shares o/s Jefferies: David Steinberg – 8.1 million options & warrants o/s Cantor Fitzgerald: Brandon Folkes Optinose Investor Contact

  18. Slide 18: Building a Leading ENT / Allergy Specialty Company

    Building a Leading ENT / Allergy Specialty Company Corporate Presentation M a r c h 6 , 2 0 1 9

OptiNose — Q4 2018 Earnings Presentation on 6ix